AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Geneesmiddelenfabrikanten algemeen

Mr. Chris  Sheldon

Head of Investor Relations

Ms. Katarina  Ageborg

EVice President of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board

Mr. Marc  Dunoyer

Chief Executive Officer of Alexion & Chief Strategy Officer

Dr. Ruud  Dobber Ph.D.

Executive Vice-President of BioPharmaceuticals Business Unit

Mr. Leon  Wang

Executive Vice President of International & China President

Mr. Andrew P. Barnett

Gonzalo  Vina

Head of Global Media Relations

Dr. Menelas  Pangalos Ph.D.

EVice President of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board

Dr. Susan Mary Galbraith M.D., Ph.D.

Executive Vice President of Oncology Research & Development

Mr. Pascal  Soriot D.V.M., M.B.A.

Chief Executive Officer & Executive Director

Naam	Marktwaarde
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.	0M
Otsuka Holdings Co., Ltd.	0M
Merck & Co., Inc.	0M
Amgen Inc.	0M
Hunan Jingfeng Pharmaceutical Co.,Ltd.	0M
JCR Pharmaceuticals Co., Ltd.	0M
Bristol-Myers Squibb Company	0M
GSK plc	0M
Luye Pharma Group Ltd.	0M
Mayne Pharma Group Limited	0M
Horizon Therapeutics Public Limited Company	0M

AstraZeneca PLC

AstraZeneca PLC Concurrenten Lijst

Belangrijkste concurrenten